Fig. 5From: Response to PD-1 inhibitor in SMARCB1‑deficient undifferentiated rectal carcinoma with low TMB, proficient MMR and BRAF V600E mutation: a case report and literature reviewImmunohistochemistry for therapeutic markers in tumor cells. A-D MLH1, MSH2, MSH6 and PMS2 indicated proficient MMR. E and F BRAF V600E and p53 mutant protein expression were strong and diffuseBack to article page